our year Slide begin starting X. Mojdeh. Thanks, results, with financial full with We'll
billion, supply. on $X.XX more X.X% revenue we were approximately a reported revenues an supply basis of XXXX growth mid-single-digit $XX with basis. decline stable than impacted Our million product XXXX product representing growth saw on in by organic and the portfolio offset a on was challenges growth which holds, the quality-related organic X.X% and
$XX revenue supply portfolio challenges. us this approximate of unaffected the give acquisition differentiated our the Our by across to organic We continues by and an reported from confidence many strength saw portfolio. net year areas drive growth. was our revenue This growth the million X.X% offset decline of to contribution in above-market Acclarent parts durable
Tissue posted portfolio, our EVD performance In Mayfield catheters our AmnioCell. of a our and Technologies, at including DuraSorb digits Capital. CFS mid-single contributed UBM business, flow franchise, In and number delivered valves, DuraGen double-digit disposables, reconstruction our [indiscernible] while portfolio delivered above also results, we products inclusive double-digit in we or CereLink Services that growth. wound programmable significant growth, have growth
for to year, in $X.XX, was XXXX. year the EPS the XX.X% down the with adjusted spending offset year. in implemented the investments The versus client supply by Our master additional due partially challenges EPS during mainly along plan, was reductions reduction during
the to half compliance the points XXX Looking the the investments margins for plan. year XX.X% challenges XXXX and second gross P&L, were middle of master at supply in due down our basis versus the
Turning to EBITDA. adjusted
Our to was year margin compared basis XXXX. points XXX EBITDA full XX% adjusted down
the challenges in of strategic and margin year. we investments key the EBITDA while impact adjusted plan maintained implementation spending Our the reductions the throughout supply performance of priorities reflects master compliance and
flow Operating for flow cash of XX.X%. million cash with conversion full the free a year was $XXX.X
financial Our flow infrastructure versus manufacturing cash rate cash declined to improve conversion quarter Slide X, operating free On results. invested and we cover flow fourth XXXX our in reliability. I will supply as
historical in were of organic shipping of growth fourth We Skin revenue on sequential the reported return $XXX saw $XX million holds, by representing quarter million, basis revenue a the XX.X% of typical of Integra revenues to driven levels quarter increase and a an X.X%. clearance seasonality. third step-up Our
XXXX up for was to EPS quarter the range. adjusted and guidance above $X.XX, Our compared our X%
basis a adjusted Our the EPS XXX XXXX adjusted point from tax rate. a reduction includes $X.XX benefit in
Looking at basis XX.X% middle the up primarily margins versus the the gross XX for revenue of points mix. P&L, to quarter, fourth due favorable were XXXX,
quarter, compared was margin XXX adjusted our fourth to the XXXX. EBITDA down For points XX.X%, basis
The XX.X%. gross the from $XX.X integration to impact cash for Operating with fourth cash from of clear was order offset million the favorable flow year-on-year cutover the free a margins, margin timing a flow certain and decline of conversion reflects cash the by expenses. operating temporary quarter modest
reported organic acquisition quarter. basis on expectations. dive We'll prior fourth our into revenue X. performance an revenues our and was Reported were for million, in reported the X.X% deeper integration Turning fourth by from quarter $XXX.X of with to basis the line an a Slide driven CFS take growth CFS largely the with in a Acclarent year. Outside on XX.X% increase highlights
shipping on driven of delivered to BactiSeal sales treatment quarter majority clear the an in lines, continued market. able performance of strength the management Global X.X% line differentiated holds growth our hydrocephalus. product digits, for grew reflecting with third solutions a were by segment grew as level, experienced in and primarily CerebroFlo strong of the and the basis double in CSF At of low organic we the Neurosurgery the our
CereLink flow sales and fueled monitors catheters. EVD monitoring, by and In neuro of increased revenues ICP BactiSeal single our CerebroFlo by high digits, strong our
continue and by our to primarily catheters. In drainage CUSA We monitoring single-digit we in growth, reinforce disposables. driven ICP position Energy, leadership experienced low Advanced
and repair of dural and a in [indiscernible] we strips. to quarter franchise, due third the largely recall our single-digit access saw decline, Lastly, our low
The to offset from by decline continued performance robust generate DuraGen, and Mayfield, DuraSeal strong was demand. partially which
the for capital site business. grew instruments, in was strong Our capital reflecting mid-single alternative by digits, our for sales were in timing. due the sales growth offset approximately to order sales funnels decreases robust flat quarter as In hospitals
we U.S. than the Shifting holds in international single to in were cleared later our shipping as low down Sales digits International. markets
year. prior segment double-digit Technologies by Slide DuraSorb, the Tissue our growth UBM double-digit seeing the increased the a reported in DuraSorb, remain which X. UBM Fourth franchise organic portfolio. Technologies sales driven both model Tissue our in from on quarter deal ahead reconstruction the robust our X.X% and compared remains to in basis by X% by We and AmnioFill. our Moving we of on wound grew seen and have growth to we're portfolio growth
We in also delivered growth skin. Integra mid-single-digit
We which and broad underscores remain business. sales by growth the long-term XX% our In down portfolio, the strength reconstruction delays. wound last of to component were this encouraged year resilience due supply private of versus label, potential
sales skin. longer inventory time international on digits down to were low in Finally, Integra lines due Tissue double Technologies recovery
I If and update brief balance you X, structure turn sheet, provide cash capital to on a our flow. will Slide
was $XX.X was cash $XX.X million CapEx. During and was free the flow the million, XX.X% quarter. flow for reflecting conversion in cash Free increased quarter, flow cash investment operating
December ratio $X.X and billion, of was Xx. our leverage total debt was XX, As net consolidated
XXXX. liquidity under investments total Xx of remainder available company the covenant revolving Max debt including is current quarter in ratio of had through under The facility. $XXX and credit short-term the million our our Our $X.X leverage cash billion, and third
adjusted our guidance provide and earnings first per year share will I for the full XX, Slide quarter On revenue and XXXX. consolidated
$XXX approximate X.X% to First an XX versus the to million point between from representing and year quarter of million, revenues the basis are prior forecasted reported $XXX range X.X% be FX. headwind includes in to growth
X.X% growth organic range the expect of to minus in minus We X.X%.
of to for reflects compliance strong holds quarter in our forecast $XX in already products, offset primarily first part million over the carried global holds $XX Our XXXX demand of identified as million quality-related and ship from approximately million $X master plan. quality-related an continued shipping our by incremental
a slower guidance for Skin. reflects Our first Integra also production quarter ramp
some fully with may While historical catch-up, from we in likely QX. constraints than in combined Skin and scheduled the and equipment in that returned us experienced safety maintenance demand meeting rates lower historical into stock run Integra QX will some prevent upgrades, our supply result
that XXXX. improvements production planned are optimistic have returning about Skin Integra progressing well, in We normal and are we levels to
Acclarent reflecting be full master to forecasted for For $X.XX the from are billion portfolio execution the revenues offset plan. our of of range a by demand $X.XX to XXXX, differentiated billion, disruption year supply for of full revenue, in the the continued year potential compliance
X.X% We expect to FX an point of X.X% full of and XX approximately year reported including organic basis an to X%. revenue growth growth X% headwind approximate and
in a primarily We increase by year sequential revenue and growth, expect seasonality. to clearance unfolds, current see driven demand our as performance of quality-related holes normal the
we production private issues half. label to and in a the see component improvement Additionally, expect in increase Skin from supply resolution the sequential of second Integra
Turning to adjusted earnings guidance.
incremental $X.XX driven investments quarter, EPS the to first to challenges and plan. we in expect adjusted master be supply the For compliance $X.XX, by
the per to the of XXX margin an in in plan an approximate rate increase the decrease the share, $X.XX master EPS versus compliance be adjusted year, XX of the to basis in For gross adjusted our investments point full from XXXX. approximate $X.XX basis our growth in reflecting range business revenue we point and expect tax
Our reflects profitability. managing while plans for also key management to adjusted maintain guidance careful investments our cost EPS
we first reference, turn XX. key your inputs modeling call guidance as as well have full to quarter year assumptions back and will key underlying Mojdeh. Slide I For the included on our that, With the